Atorvastatin API Market Analysis

Global Atorvastatin API Market Overview

Atorvastatin API Market Size was valued at USD 1.61 Billion in 2023. The Atorvastatin API market industry is projected to grow from USD 1.73 Billion in 2024 to USD 2.87 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.53% during the forecast period (2024 - 2032).A large volume of kidney problems, combined with a high measurement of the medicine used to reduce cholesterol levels in the elderly are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Atorvastatin API Market Trends

• Growing cardiovascular disease is driving the market growth

Market CAGR for atorvastatin API is being driven by the rising cardiovascular disease. Cardiovascular disease is the major cause of death worldwide. The demand for atorvastatin API, a cholesterol-lowering medicine, is predicted to rise as the prevalence of these disorders rises. Generic medications are often less expensive than branded drugs, making them more accessible. This is driving the demand for generic atorvastatin API. New atorvastatin formulations that are more effective and have fewer negative effects are being explored. These innovative formulations are projected to increase market share in the following years. Atorvastatin is a lipid-lowering drug used to treat high cholesterol. It is the world's most often prescribed cholesterol-lowering medicine. The rising frequency of cardiovascular illnesses is the primary driving force behind the atorvastatin API industry. According to the World Health Organisation, cardiovascular illnesses are the biggest cause of death worldwide.

Rising demand for generic medications is also driving expansion in this industry. Generic medications are often less expensive than branded drugs, making them more accessible. The increasing emphasis on research and development of novel atorvastatin formulations will likely fuel market expansion. New atorvastatin formulations that are more effective and have fewer negative effects are being explored.Personalized medicine is a branch of medicine that considers a patient's genetic composition and other criteria when making treatment decisions. This is intended to result in the creation of new atorvastatin formulations customized to individual patient demands. Patient compliance is a significant obstacle in the treatment of cardiovascular illnesses. New atorvastatin formulations that are easier to consume and have fewer side effects are intended to increase patient compliance and, as a result, treatment success. Electronic health records (EHRs) and telemedicine are digital technologies becoming increasingly essential in healthcare. These solutions will likely improve patient care by streamlining the atorvastatin API supply chain.

A significant volume of kidney problems, combined with a high measurement of the medication in the elderly to regulate their cholesterol levels, should bode well for the Atorvastatin API Market. Government agencies' endorsement of large-scale medicine manufacturing could propel the atorvastatin API sector forward. Recently, the FDA granted Morepen Laboratories permission to manufacture atorvastatin calcium for export to the United States. Severe guidelines established by government organizations and consistency in transitioning to green manufacturing practices can bode well for the Atorvastatin API Market Share. In any case, unfavorable effects of the drug may impede the growth of the Atorvastatin API Market. Thus, driving the Atorvastatin API market revenue.

Atorvastatin API Market Segment Insights

Atorvastatin API Application Insights

Based on application, the Atorvastatin API market segmentation includes hypercholesterolemia, hypertriglyceridemia, dyslipidemia and others. The hypercholesterolemia segment dominated the market, accounting for 35% of market revenue. Atorvastatin API is a cholesterol-lowering drug used to treat hypercholesterolemia. It belongs to the statin class of medicines, which function by preventing cholesterol formation in the liver. Atorvastatin API is a generic medication marketed under Lipitor and Caduet. High cholesterol levels, a major risk factor for heart disease, stroke, and other cardiovascular issues, are treated with atorvastatin API. It can also be used to treat high triglyceride levels as well as to prevent heart attacks and strokes in high-risk individuals. Atorvastatin API is taken orally once a day. It normally begins at a low dose and gradually increases until the appropriate cholesterol level is obtained. Muscle discomfort, nausea, and headache are the most prevalent atorvastatin API side effects. Serious side effects of atorvastatin API are uncommon. However, they can include liver damage, kidney issues, and muscle disintegration. Atorvastatin API is not for everyone. It should not be used by anyone pregnant, breastfeeding, or with liver or renal problems. It should also be used cautiously by persons taking other medications that may interact with it.

Figure 1: Atorvastatin API Market, by Application, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Atorvastatin API Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Atorvastatin API market area will dominate this market, The increased incidence of cancer and other lifestyle-related disorders promotes R&D, ultimately driving the market.

Hence, the major countries studied in the market report are The US, Canada, German, the UK, Italy,France, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ATORVASTATIN API MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Atorvastatin API market accounts for the second-largest market share. The market will likely be driven by a rise in research funding and the local presence of key industry players in this region. The number of biopharmaceutical businesses in Europe is expanding due to increased investment. Further, the German Atorvastatin API market held the largest market share, and the Atorvastatin API market in the United Kingdom was the fastest growing in the European region.

The Asia-Pacific Atorvastatin API Market is expected to grow at the fastest CAGR from 2024 to 2032. The existence of economies such as China and India, on which the world relies for low-cost API production, is advantageous to the region.Moreover, China’s Atorvastatin API market held the largest market share, and The Indian Atorvastatin API market was the Asia-Pacific region's fastest-growing market.

Atorvastatin API Key Market Players & Competitive Insights

Leading market companies are extensively spending R&D on increasing their product lines, which will help the Atorvastatin API market grow even more. Important market developments include new product releases, contractual agreements, acquisitions and mergers, greater investments, and collaboration with other organizations. The Atorvastatin API industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.

Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Atorvastatin API industry to serve clients and expand the market sector. The Atorvastatin API industry has provided some of the most important benefits recently. Major players in the Atorvastatin API market, including Zydus Lifesciences Limited and others, are attempting to increase market demand by investing in research and development operations.

Zydus Lifesciences Limited, originally Cadila Healthcare Limited, is an Indian multinational pharmaceutical business based in Ahmedabad that mostly manufactures generic pharmaceuticals. Zydus Cadila develops and manufactures a wide range of pharmaceuticals, diagnostics, herbal products, skincare products, and other OTC items from twenty-five pharmaceutical manufacturing facilities in India. After signing a voluntary license agreement with Gilead in late 2015, the company began producing generics for hepatitis C therapy (sofosbuvir, marketed under SoviHep). The company manufactures active medicinal ingredients in four locations in India: Ankleshwar, Vadodara, and Ahmedabad. In October 2018, Zydus Cadila announced Thursday that it had acquired approval from the US Food and Medication Administration to market the cholesterol-lowering medication Atorvastatin Calcium tablets. The Ahmedabad-based company has acquired final approval from the US Food and Medicine Administration (USFDA) to market the medicine in doses of 10 mg, 20 mg, 40 mg, and 80 mg, according to Zydus Cadila.

 Lupin is a worldwide pharmaceutical firm based in Mumbai, India, focusing on innovation. The company develops and commercializes various biotechnology products, branded and generic formulations, and APIs in over 100 markets across Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East. The company is a market leader in the anti-diabetic, cardiovascular, and respiratory segments and has a substantial presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health segments. In June 2019, Lupin Limited (Lupin) announced the launch of Atorvastatin Calcium Tablets USP, 20 mg, 10 mg, 40 mg, and 80 mg, following the US Food and Drug Administration (US FDA) approval. Lupin's Nagpur factory in India will manufacture the product. Atorvastatin is also used to reduce the chance of a heart attack or stroke in people with cardiovascular disease, diabetes, or other risk factors such as eye issues, kidney illness, or high blood pressure.

Key Companies in the Atorvastatin API market include

• Teva Pharmaceutical Industries Ltd (Israel)


• Sun Pharmaceutical Industries Ltd (India)


• Centrient Pharmaceuticals (The Netherlands)


• Morepen Laboratories Ltd (India)


• Dr. Reddy’s Laboratories Ltd (India)


• Anuh Pharma Ltd (India)


• Jubilant Life Sciences Ltd (India)


• Ind-Swift Labs Ltd (India)


• Zhejiang Hisun Pharmaceutical Co Ltd (China)


• Cadila Pharmaceuticals (India).

June 2021:Centrient Pharmaceuticals has begun expanded statin production at its active pharmaceutical ingredient (API) manufacturing facilities in Toansa, India. The Dutch business claimed that with the start-up of its second unit at the facility, it had doubled capacity for Atorvastatin and Rosuvastatin, satisfying rising demand for its sustainably produced portfolio.Statins are currently the most prescribed medicine class in the world for treating excessive cholesterol and cardiovascular disease, and they are also among the top-selling drugs. According to Centrient, markets for Atorvastatin and Rosuvastatin have continuously increased in recent years, owing to the sustained incidence of high cholesterol concerns, replacement of previous generation statins, and market genericization.

Atorvastatin API Market Segmentation

Atorvastatin API Type Outlook

• Hypercholesterolemia


• Hypertriglyceridemia


• Dyslipidemia


• Others

Atorvastatin API Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America